Cargando…

The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds

Non-invasive assessment of the biodistribution is of great importance during the development of new pharmaceutical compounds. In this contribution, the applicability of in ovo MRI for monitoring the biodistribution of MR contrast agent-labelled compounds was investigated in mamaria carcinomas xentot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuo, Zhi, Syrovets, Tatiana, Wu, Yuzhou, Hafner, Susanne, Vernikouskaya, Ina, Liu, Weina, Ma, Genshan, Weil, Tanja, Simmet, Thomas, Rasche, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413881/
https://www.ncbi.nlm.nih.gov/pubmed/28466861
http://dx.doi.org/10.1038/srep46690
_version_ 1783233252313530368
author Zuo, Zhi
Syrovets, Tatiana
Wu, Yuzhou
Hafner, Susanne
Vernikouskaya, Ina
Liu, Weina
Ma, Genshan
Weil, Tanja
Simmet, Thomas
Rasche, Volker
author_facet Zuo, Zhi
Syrovets, Tatiana
Wu, Yuzhou
Hafner, Susanne
Vernikouskaya, Ina
Liu, Weina
Ma, Genshan
Weil, Tanja
Simmet, Thomas
Rasche, Volker
author_sort Zuo, Zhi
collection PubMed
description Non-invasive assessment of the biodistribution is of great importance during the development of new pharmaceutical compounds. In this contribution, the applicability of in ovo MRI for monitoring the biodistribution of MR contrast agent-labelled compounds was investigated in mamaria carcinomas xentotransplanted on the chorioallantoic membrane (CAM) exemplarily for Gd-DOTA and cHSA-PEO (2000)16-Gd after systemic injection of the compounds into a chorioallantoic capillary vein. MRI was performed directly prior and 30 min, 3 h, 5 h, 20 h, and 40 h after injection of the compound. The biodistribution of injected compounds could be assessed by MRI in different organs of the chicken embryo as well as in xenotransplanted tumors at all time points. A clearly prolonged enhancement of the tumor substrate could be shown for cHSA-PEO (2000)(16)-Gd. In conclusion, high-resolution in ovo MR imaging can be used for assessment of the in vivo biodistribution of labelled compounds, thus enabling efficient non-invasive initial testing.
format Online
Article
Text
id pubmed-5413881
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-54138812017-05-03 The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds Zuo, Zhi Syrovets, Tatiana Wu, Yuzhou Hafner, Susanne Vernikouskaya, Ina Liu, Weina Ma, Genshan Weil, Tanja Simmet, Thomas Rasche, Volker Sci Rep Article Non-invasive assessment of the biodistribution is of great importance during the development of new pharmaceutical compounds. In this contribution, the applicability of in ovo MRI for monitoring the biodistribution of MR contrast agent-labelled compounds was investigated in mamaria carcinomas xentotransplanted on the chorioallantoic membrane (CAM) exemplarily for Gd-DOTA and cHSA-PEO (2000)16-Gd after systemic injection of the compounds into a chorioallantoic capillary vein. MRI was performed directly prior and 30 min, 3 h, 5 h, 20 h, and 40 h after injection of the compound. The biodistribution of injected compounds could be assessed by MRI in different organs of the chicken embryo as well as in xenotransplanted tumors at all time points. A clearly prolonged enhancement of the tumor substrate could be shown for cHSA-PEO (2000)(16)-Gd. In conclusion, high-resolution in ovo MR imaging can be used for assessment of the in vivo biodistribution of labelled compounds, thus enabling efficient non-invasive initial testing. Nature Publishing Group 2017-05-03 /pmc/articles/PMC5413881/ /pubmed/28466861 http://dx.doi.org/10.1038/srep46690 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Zuo, Zhi
Syrovets, Tatiana
Wu, Yuzhou
Hafner, Susanne
Vernikouskaya, Ina
Liu, Weina
Ma, Genshan
Weil, Tanja
Simmet, Thomas
Rasche, Volker
The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title_full The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title_fullStr The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title_full_unstemmed The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title_short The CAM cancer xenograft as a model for initial evaluation of MR labelled compounds
title_sort cam cancer xenograft as a model for initial evaluation of mr labelled compounds
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413881/
https://www.ncbi.nlm.nih.gov/pubmed/28466861
http://dx.doi.org/10.1038/srep46690
work_keys_str_mv AT zuozhi thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT syrovetstatiana thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT wuyuzhou thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT hafnersusanne thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT vernikouskayaina thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT liuweina thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT magenshan thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT weiltanja thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT simmetthomas thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT raschevolker thecamcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT zuozhi camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT syrovetstatiana camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT wuyuzhou camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT hafnersusanne camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT vernikouskayaina camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT liuweina camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT magenshan camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT weiltanja camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT simmetthomas camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds
AT raschevolker camcancerxenograftasamodelforinitialevaluationofmrlabelledcompounds